International Journal of Medical and Pharmaceutical Research
2024, Volume-5, Issue-3
Original Article
Acquired Hypernatremia in ICU Patients
 ,
 ,
 ,
Published
May 15, 2024
Abstract

A common ailment in intensive care units (ICUs), hypernatremia presents serious hazards to the physiological balance of patients and can sharply increase the death rate of critically ill patients. To determine if the cause of this electrolyte imbalance is an excess of sodium consumption or a lack of free water availability, a thorough clinical evaluation and urine electrolyte testing are frequently required. Careful monitoring of salt-to-water ratios becomes crucial in the complicated setting of intensive care units (ICUs), where patients may suffer from cognitive deficits that compromise natural physiological mechanisms such as thirst management. In order to properly treat hypernatremia, healthcare professionals—especially intensivists—play a crucial role in assuring watchful surveillance and prompt action. Treatment strategies typically involve the administration of free water and/or diuretics to enhance salt excretion, with correction rates carefully tailored to the individual patient's condition to mitigate risks such as cerebral edema. This multifaceted approach to managing hypernatremia underscores the importance of a coordinated and interdisciplinary effort in ICUs to optimize patient care and outcomes while minimizing potential complications associated with electrolyte disturbances.

Recommended Articles
Loading Image...
Volume-5, Issue-3
Citations
2445 Views
417 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved